Loading provider…
Loading provider…
Medical Oncology Physician in Orange, CA
NPI: 1093822017Primary Practice Location
UNIVERSITY OF CALIFORNIA IRVINE MEDICAL CENTER
101 The City Dr S, Orange, CA
Primary Employer
UCI Department of Medicine
medschool.uci.edu
HQ Phone
Get MD Warren's Phone NumberMobile
Get MD Warren's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1987 - 2027

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
Cedars-Sinai Medical Center
Residency • Internal Medicine
1986 - 1990
Internship • Internal Medicine
1986 - 1987
Chicago Medical School at Rosalind Franklin University of Medicine and Science
Medical School
Until 1986
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 101 | 293 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 36 | 36 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 32 | 41 |
| 4 | 99441Physician telephone patient service, 5-10 minutes of medical discussion | 13 | 16 |
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer
Authors: Robert Morgan, Stephen Forman, Neil Kogut, George Somlo, Kim Margolin, Lucille Leong, Arturo Molina
Journal: Br J Cancer
Authors: Merry Tetef, Robert Morgan, Przemyslaw Twardowski, Yun Yen, Dean Lim, George Somlo, Kim Margolin, Lucille Leong
Journal: Cancer Chemother Pharmacol
Publication Date: 2004-06-02
Authors: Guan, Min, Su, Leila, Yuan, Yate-Ching, Li, Haiqing, Chow, Warren A
Journal: Sci Rep
Publication Date: 2015-04-16
Lead Sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd
Intervention / Treatment: DRUG: SGN1
Lead Sponsor: Adaptimmune
Intervention / Treatment: BIOLOGICAL: ADP adoptive cell therapy
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Dulaglutide, DRUG: tirzepatide